Tempus AI $TEM ( ▲ 4.51% ) is catching a fresh bid from investors after posting early, preliminary results that came in ahead of Wall Street expectations. The Chicago-based cancer diagnostics company surged early Monday after releasing updated financial figures ahead of a major investor conference appearance later today.
The numbers are not final, but they were strong enough to light up a stock that’s already been on a tear.
Early Q4 Sales Beat Wall Street Estimates
Tempus reported preliminary Q4 sales of roughly $367 million, topping expectations of about $361 million.
More notably, diagnostics revenue more than doubled to $266 million, reinforcing the view that the company’s core cancer testing business is scaling fast as adoption expands.
Tempus also posted an updated corporate presentation on its website ahead of its scheduled appearance at the JPMorgan Healthcare Conference today at 4:30 p.m. ET.
Not Final Results Yet
Tempus emphasized that it has not completed its official Q4 or full-year 2025 financial statements. The company typically files final results in February, meaning these are essentially early signals, not the fully audited picture.
Still, in biotech and healthcare, “preliminary beats” are often enough to move the stock because they shape narrative before the official filing lands.
Growth Stock Momentum Is Doing the Rest
Wall Street still expects Tempus to remain unprofitable through 2027, but investors have been rewarding revenue growth and momentum.
Tempus shares gained 75% last year, and through Monday’s open the stock is already up another 24% in 2026.
Bottom line: Tempus is proving it can outgrow skepticism. Even with losses expected for years, better-than-expected sales, surging diagnostics revenue, and high investor attention are keeping this one in breakout mode.